SAFETY DATA FROM AN EXPANDED ACCESS PROGRAM (EAP) OF NIVOLUMAB (NIVO) IN COMBINATION WITH IPILIMUMAB (IPI) IN PATIENTS WITH ADVANCED MELANOMA (MEL)

被引：0
|
作者：
Chapman, Paul B. [1 ]
Sznol, Mario [2 ]
Lao, Christopher D. [3 ]
Gonzalez, Rene [4 ]
Daniels, Gregory A. [5 ]
Thompson, John A. [6 ]
Kudchadkar, Ragini R. [7 ]
Sharfman, William H. [8 ]
Atkins, Michael B. [9 ]
Pavlick, Anna C. [10 ]
Infante, Jeffrey R. [11 ]
Kim, Kevin B. [12 ]
Weber, Jeffrey S. [13 ]
Nair, Suresh [14 ]
Cowey, Lance [15 ]
Lipson, Evan J. [8 ]
Lee, Sue [16 ]
Avila, Alexandre [16 ]
Hodi, Stephen [17 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Yale Canc Ctr, New Haven, CT USA
[3] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
[4] Univ Colorado, Ctr Canc, Denver, CO 80262 USA
[5] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA
[6] Univ Washington, Seattle, WA 98195 USA
[7] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[8] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA
[9] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA
[10] NYU, New York, NY USA
[11] Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA
[12] Calif Pacific Ctr Melanoma Res, San Francisco, CA USA
[13] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[14] Lehigh Valley Hosp, Allentown, PA USA
[15] Texas Oncol Baylor Charles A Sammons Canc Ctr, Dallas, TX USA
[16] Bristol Myers Squibb, Princeton, NJ USA
[17] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
219
引用
收藏
页码：119 / 119
页数：1
相关论文
共 50 条
  • [1] Safety data from an expanded access program (EAP) of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (MEL).
    Chapman, Paul B.
    Sznol, Mario
    Lao, Christopher
    Gonzalez, Rene
    Daniels, Gregory A.
    Thompson, John A.
    Kudchadkar, Ragini Reiney
    Sharfman, William Howard
    Atkins, Michael B.
    Pavlick, Anna C.
    Infante, Jeffrey R.
    Kim, Kevin
    Weber, Jeffrey S.
    Patel, Sapna Pradyuman
    Nair, Suresh
    Cowey, C. Lance
    Lipson, Evan J.
    Lee, Sue
    Avila, Alexandre
    Hodi, F. Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] Overall survival (OS) analysis from an expanded access program (EAP) of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (MEL).
    Hogg, David
    Chapman, Paul B.
    Sznol, Mario
    Lao, Christopher D.
    Gonzalez, Rene
    Daniels, Gregory A.
    Smylie, Michael
    Kudchadkar, Ragini Reiney
    Thompson, John A.
    Sharfman, William Howard
    Atkins, Michael B.
    Pavlick, Anna C.
    Jiang, Joel
    Avila, Alexandre
    Demelo, Sheena
    Hodi, F. Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] SAFETY PROFILE OF NIVOLUMAB (NIVO) AND IPILIMUMAB (IPI) COMBINATION THERAPY IN PATIENTS WITH ADVANCED MELANOMA (MEL)
    Sznol, Mario
    Ferrucci, Pier
    Hogg, David
    Atkins, Michael
    Wolter, Pascal
    Guidoboni, Massimo
    Lebbe, Celeste
    Kirkwood, John
    Schachter, Jacob
    Daniels, Gregory
    Hassel, Jessica
    Cebon, Jonathan
    Gerritsen, Winald
    Atkinson, Victoria
    Thomas, Luc
    Mccaffrey, John
    Power, Derek
    Jiang, Joel
    Hodi, Stephen
    Wolchok, Jedd
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 118 - 118
  • [4] Overall survival and safety experience from an expanded access program (EAP) of nivolumab (NIVO) for patients with advanced melanoma (MEL) who progressed after prior ipilimumab (IPI) treatment
    Barros e Silva, Milton
    Schmerling, Rafael
    de Melo, Andreia Cristina
    Azevedo, Sergio
    Garicochea, Bernardo
    McWhirter, Elaine
    Smylie, Michael
    Gifoni, Markus
    dos Anjos, Carlos Henrique
    Petrella, Teresa
    Chacon, Matias
    Greco, Martin
    Nair, Suresh
    Avila, Alexandre
    Demelo, Sheena
    Jiang, Joel
    Ernst, Scott
    CANCER RESEARCH, 2017, 77
  • [5] Safety profile of nivolumab (NIVO) and ipilimumab (IPI) combination therapy in patients (pts) with advanced melanoma (MEL)
    Sznol, M.
    Ferrucci, P. F.
    Hogg, D.
    Atkins, M.
    Wolter, P.
    Guidoboni, M.
    Lebbe, C.
    Kirkwood, J.
    Schachter, J.
    Daniels, G.
    Hassel, J.
    Cebon, J.
    Gerritsen, W.
    Atkinson, V.
    Thomas, L.
    McCaffrey, J.
    Power, D.
    Jiang, J.
    Hodi, F. S.
    Wolchok, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [6] Efficacy of nivolumab and ipilimumab (Nivo plus Ipi) combination in melanoma patients (pts) treated at a single institution on an expanded-access program (EAP).
    Shoushtari, Alexander Noor
    Navid-Azarbaijani, Pedram
    Friedman, Claire Frances
    Panageas, Katherine
    Postow, Michael Andrew
    Callahan, Margaret K.
    Momtaz, Parisa
    Campbell, Shonnette C.
    Shames, Yelena
    Prempeh-Keteku, Nana A.
    Nwaedozie, Kasiemobi
    Wolchok, Jedd D.
    Chapman, Paul B.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] Characterisation of Complete Responses (CRS) in Patients With Advanced Melanoma (MEL) who Received the Combination of Nivolumab (NIVO) and Ipilimumab (IPI), NIVO, or IPI Alone
    Robert, Caroline
    Larkin, James
    Ascierto, Paolo A.
    Long, Georgina V.
    Hassel, Jessica C.
    Schadendorf, Dirk
    Hodi, F. Stephen
    Lebbe, Celeste
    Grob, Jean-Jacques
    Grossmann, Kenneth
    Wagstaff, John
    Chesney, Jason
    Hogg, David
    Bechter, Oliver
    Marquez-Rodas, Ivan
    Pavlick, Anna C.
    DanaWalker
    Bhore, Rafia
    Postow, Michael A.
    Wolchok, Jedd D.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 136 - 137
  • [8] Characterization of complete responses (CRs) in patients with advanced melanoma (MEL) who received the combination of nivolumab (NIVO) and ipilimumab (IPI), NIVO or IPI alone
    Robert, C.
    Larkin, J.
    Ascierto, P. A.
    Long, G. V.
    Hassel, J. C.
    Schadendorf, D.
    Hodi, F. S.
    Lebbe, C.
    Grob, J-J.
    Grossmann, K.
    Wagstaff, J.
    Chesney, J.
    Hogg, D.
    Bechter, O.
    Marquez-Rodas, I.
    Pavlick, A. C.
    Walker, D.
    Bhore, R.
    Postow, M. A.
    Wolchok, J. D.
    ANNALS OF ONCOLOGY, 2017, 28
  • [9] Toxicity associated with ipilimumab and nivolumab (Ipi plus Nivo) combination therapy in melanoma patients (pts) treated at a single-institution under an expanded-access program (EAP).
    Friedman, Claire Frances
    Navid-Azarbaijani, Pedram
    Shoushtari, Alexander Noor
    Campbell, Shonnette C.
    Callahan, Margaret K.
    Momtaz, Parisa
    Prempeh-Keteku, Nana A.
    Postow, Michael Andrew
    Shames, Yelena
    Wolchok, Jedd D.
    Chapman, Paul B.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [10] IPILIMUMAB (IPI) EXPANDED ACCESS PROGRAM (EAP) FOR PATIENTS (PTS) WITH STAGE III/IV MELANOMA: SAFETY DATA BY SUBGROUPS
    Lawrence, D.
    McDermott, D. F.
    Hamid, O.
    Weber, J. S.
    Wolchok, J. D.
    Richards, J.
    Amin, A.
    Bennett, K.
    Balogh, A.
    Hodi, F. S.
    ANNALS OF ONCOLOGY, 2012, 23 : 368 - 368
12345